<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39554397</PMID><DateRevised><Year>2024</Year><Month>11</Month><Day>18</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2322-2379</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>Galen medical journal</Title><ISOAbbreviation>Galen Med J</ISOAbbreviation></Journal><ArticleTitle>Evaluating the Therapeutic Effect of Sofosbuvir in Outpatients with COVID-19: A Randomized Clinical Trial Study.</ArticleTitle><Pagination><StartPage>1</StartPage><EndPage>7</EndPage><MedlinePgn>1-7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.31661/gmj.v12i.3035</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The coronavirus disease 2019 (COVID-19) pandemic has engendered scores of deaths worldwide. Just as the development of varying procedures during the pandemic has helped inhibit the disease, none is considered a definitive treatment protocol for this problem, as each induces some clinical complications pertinent to the disease. This study thus assessed the early use of sofosbuvir in outpatients with mild COVID-19.</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">This randomized clinical trial study was conducted on 360 patients with mild COVID-19 infection at 17 Shahrivar Ahvaz Health Center. These patients were randomly divided into the intervention and control groups. Both the control and intervention groups received 400 mg of sofosbuvir and a placebo for seven days, respectively. After 14 days from the onset of the treatment, the duration of symptoms, the necessity of hospitalization, the mean of hospitalization duration, and mortality were assessed.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The most common symptoms in the intervention and control groups were coughs with a frequency of 46 (25.6%) and 54(30%), respectively. The two groups showed no statistically significant difference in the frequency of the first observed clinical symptom related to the disease (P=0.2). The mean days that the patients were symptomatic in the control group were 14±4.17, whereas, in the intervention group, it was 12.12±3.15 (P=0.08). The frequency of hospitalization in the control and intervention groups was 7 (3.8%) and 4 (2.22%), respectively (P=0.11). Moreover, the mean days of hospitalization in the control and the intervention groups were 4±1.1 and 3±0.8, respectively (P=0.15). In addition, the two groups had a similar frequency of hospitalization in the ICU (0) and mortality rate (0).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Sofosbuvir alone cannot play a significant role in the treatment of outpatients with mild COVID-19.</AbstractText><CopyrightInformation>Copyright© 2024, Galen Medical Journal.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Haddadzadeh Shoushtari</LastName><ForeName>Maryam</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Air Pollution and Respiratory Diseases Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Raji</LastName><ForeName>Hanieh</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Air Pollution and Respiratory Diseases Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Borsi</LastName><ForeName>Seyed Hamid</ForeName><Initials>SH</Initials><AffiliationInfo><Affiliation>Air Pollution and Respiratory Diseases Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tavakol</LastName><ForeName>Heshmatollah</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Air Pollution and Respiratory Diseases Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cheraghian</LastName><ForeName>Bahman</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Biostatics and Public Health, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moeinpour</LastName><ForeName>Mahtab</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pulmonology, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>02</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>Iran</Country><MedlineTA>Galen Med J</MedlineTA><NlmUniqueID>101625418</NlmUniqueID><ISSNLinking>2322-2379</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Mild Symptoms</Keyword><Keyword MajorTopicYN="N">Mortality</Keyword><Keyword MajorTopicYN="N">Sofosbuvir</Keyword></KeywordList><CoiStatement>There is no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>4</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>6</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>7</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>11</Month><Day>18</Day><Hour>16</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>11</Month><Day>18</Day><Hour>16</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>11</Month><Day>18</Day><Hour>6</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>2</Month><Day>8</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39554397</ArticleId><ArticleId IdType="pmc">PMC11568422</ArticleId><ArticleId IdType="doi">10.31661/gmj.v12i.3035</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lai CC, Wang CY, Wang YH, Hsueh SC, Ko WC, Hsueh PR. Global epidemiology of coronavirus disease 2019 (COVID-19): disease incidence, daily cumulative index, mortality, and their association with country healthcare resources and economic status . Int J Antimicrob Agents. 2020;4(55):105946–105946.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7156123</ArticleId><ArticleId IdType="pubmed">32199877</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai CC, Liu YH, Wang CY, Wang YH, Hsueh SC, Yen MY, et al. Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Facts and myths . J Microbiol Immunol Infect. 2020;3(53):404–12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7128959</ArticleId><ArticleId IdType="pubmed">32173241</ArticleId></ArticleIdList></Reference><Reference><Citation>Sterne JAC, Murthy S, Diaz JV, Slutsky AS, Villar J, Angus DC, et al. Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-analysis . Jama. 2020;13(324):1330–41.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7489434</ArticleId><ArticleId IdType="pubmed">32876694</ArticleId></ArticleIdList></Reference><Reference><Citation>Shankar-Hari M, Vale CL, Godolphin PJ, Fisher D, Higgins JPT, Spiga F, et al. Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis . Jama. 2021;6(326):499–518.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8261689</ArticleId><ArticleId IdType="pubmed">34228774</ArticleId></ArticleIdList></Reference><Reference><Citation>Zumla A, Chan JF, Azhar EI, Hui DS, Yuen KY. Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016;5(15):327–47.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7097181</ArticleId><ArticleId IdType="pubmed">26868298</ArticleId></ArticleIdList></Reference><Reference><Citation>Dustin LB, Bartolini B, Capobianchi MR, Pistello M. Hepatitis C virus: life cycle in cells, infection, and host response, and analysis of molecular markers influencing the outcome of infection and response to therapy . Clin Microbiol Infect. 2016;10(22):826–32.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5627509</ArticleId><ArticleId IdType="pubmed">27592089</ArticleId></ArticleIdList></Reference><Reference><Citation>Merat S. SD1000: High Sustained Viral Response Rate in 1361 Patients With Hepatitis C Genotypes 1, 2, 3, and 4 Using a Low-cost, Fixed-dose Combination Tablet of Generic Sofosbuvir and Daclatasvir: A Multicenter, Phase III Clinical Trial . Clin Infect Dis. 2020;10(70):2206–12.</Citation><ArticleIdList><ArticleId IdType="pubmed">31504303</ArticleId></ArticleIdList></Reference><Reference><Citation>Jockusch S, Tao C, Li X, Chien M, Kumar S, Morozova I, et al. Sofosbuvir-terminated RNA is more resistant to SARS-CoV-2 proofreader than RNA terminated by Remdesivir . SCi Rep. 2020;1(10):1–9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7538426</ArticleId><ArticleId IdType="pubmed">33024223</ArticleId></ArticleIdList></Reference><Reference><Citation>Bozorgmehr R, Amiri F, Hosein Zadeh, Ghorbani F, Khameneh Bagheri. Effect of Sofosbuvir on Length of Hospital Stay in Moderate COVID-19 Cases; a Randomized Controlled Trial . Arch Acad Emerg Med. 2022;1(10):e46–49.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9206832</ArticleId><ArticleId IdType="pubmed">35765613</ArticleId></ArticleIdList></Reference><Reference><Citation>Nourian A. Khalili H.Sofosbuvir as a potential option for the treatment of COVID-19 . Acta Biomed. 2020;2(91):239–241–239–241.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7569608</ArticleId><ArticleId IdType="pubmed">32420958</ArticleId></ArticleIdList></Reference><Reference><Citation>Sadeghi A, Ali Asgari, Norouzi A, Kheiri Z, Anushirvani A, Montazeri M, et al. Sofosbuvir and daclatasvir compared with standard of care in the treatment of patients admitted to hospital with moderate or severe coronavirus infection (COVID-19): a randomized controlled trial . J Antimicrob Chemother. 2020;11(75):3379–85.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7454592</ArticleId><ArticleId IdType="pubmed">32812039</ArticleId></ArticleIdList></Reference><Reference><Citation>Abbaspour Kasgari, Moradi S, Shabani AM, Babamahmoodi F, Davoudi Badabi, Davoudi L. Evaluation of the efficacy of sofosbuvir plus daclatasvir in combination with ribavirin for hospitalized COVID-19 patients with the moderate disease compared with standard care: a single-centre, randomized controlled trial . J Antimicrob Chemother. 2020;11(75):3373–8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7454669</ArticleId><ArticleId IdType="pubmed">32812025</ArticleId></ArticleIdList></Reference><Reference><Citation>Eslami G, Mousaviasl S, Radmanesh E, Jelvay S, Bitaraf S, Simmons B, et al. The impact of sofosbuvir/daclatasvir or ribavirin in patients with severe COVID-19 . J Antimicrob Chemother. 2020;11(75):3366–72.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7529105</ArticleId><ArticleId IdType="pubmed">32812051</ArticleId></ArticleIdList></Reference><Reference><Citation>Roozbeh F, Saeedi M, Alizadeh-Navaei R, Hedayatizadeh-Omran A, Merat S, Wentzel H, et al. Sofosbuvir and daclatasvir for the treatment of COVID-19 outpatients: a double-blind, randomized controlled trial . J Antimicrob Chemother. 2021;3(76):753–7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7798988</ArticleId><ArticleId IdType="pubmed">33338232</ArticleId></ArticleIdList></Reference><Reference><Citation>Sayad B, Khodarahmi R, Najafi F, Miladi R, Mohseni Afshar, Mansouri F, et al. Efficacy and safety of sofosbuvir/velpatasvir versus the standard of care in adults hospitalized with COVID-19: a single-centre, randomized controlled trial . J Antimicrob Chemother. 2021;8(76):2158–67.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8194643</ArticleId><ArticleId IdType="pubmed">34037760</ArticleId></ArticleIdList></Reference><Reference><Citation>Simmons B, Wentzel H, Mobarak S, Eslami G, Sadeghi A, Ali Asgari, et al. Sofosbuvir/daclatasvir regimens for the treatment of COVID-19: an individual patient data meta-analysis . J Antimicrob Chemother. 2021;2(76):286–91.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7665526</ArticleId><ArticleId IdType="pubmed">33063117</ArticleId></ArticleIdList></Reference><Reference><Citation>Zein A. Sofosbuvir with daclatasvir and the outcomes of patients with COVID-19: a systematic review and meta-analysis with GRADE assessment . Postgrad Med J. 2022;1161(98):509–514.</Citation><ArticleIdList><ArticleId IdType="pubmed">37066509</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>